7,800 Shares in Celgene Corporation (CELG) Acquired by Walter & Keenan Financial Consulting Co. MI ADV

Walter & Keenan Financial Consulting Co. MI ADV acquired a new position in Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 7,800 shares of the biopharmaceutical company’s stock, valued at approximately $1,013,000.

Several other institutional investors have also added to or reduced their stakes in the stock. State Street Corp boosted its position in shares of Celgene Corporation by 2.3% in the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after buying an additional 723,844 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Celgene Corporation by 4.9% in the 1st quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock worth $1,255,309,000 after buying an additional 472,067 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Celgene Corporation by 4.4% in the 1st quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock worth $816,733,000 after buying an additional 276,089 shares in the last quarter. Pioneer Investment Management Inc. boosted its position in shares of Celgene Corporation by 15.7% in the 1st quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock worth $650,911,000 after buying an additional 710,584 shares in the last quarter. Finally, Clearbridge Investments LLC boosted its position in shares of Celgene Corporation by 24.1% in the 1st quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock worth $572,617,000 after buying an additional 892,392 shares in the last quarter. Institutional investors and hedge funds own 79.36% of the company’s stock.

Shares of Celgene Corporation (NASDAQ CELG) opened at 139.27 on Tuesday. The firm has a 50-day moving average of $139.64 and a 200 day moving average of $129.73. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $147.17. The firm has a market cap of $108.96 billion, a P/E ratio of 43.13 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same period in the previous year, the company earned $1.44 EPS. The company’s revenue for the quarter was up 18.7% on a year-over-year basis. On average, equities research analysts anticipate that Celgene Corporation will post $7.32 EPS for the current fiscal year.

CELG has been the topic of a number of recent research reports. BidaskClub upgraded shares of Celgene Corporation from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 14th. Oppenheimer Holdings, Inc. set a $148.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a report on Wednesday, June 14th. Leerink Swann upgraded shares of Celgene Corporation from a “market perform” rating to an “outperform” rating and upped their target price for the company from $94.42 to $150.00 in a report on Friday, June 16th. They noted that the move was a valuation call. William Blair restated an “outperform” rating on shares of Celgene Corporation in a report on Monday, June 26th. Finally, BTIG Research lowered shares of Celgene Corporation from a “buy” rating to a “neutral” rating and upped their target price for the company from $96.93 to $131.70 in a report on Friday, June 30th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and twenty-two have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $150.60.

In related news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ernest Mario sold 18,506 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the sale, the director now owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 46,233 shares of company stock valued at $6,268,259. Cor

Several other institutional investors have also added to or reduced their stakes in the stock. State Street Corp boosted its position in shares of Celgene Corporation by 2.3% in the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after buying an additional 723,844 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Celgene Corporation by 4.9% in the 1st quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock worth $1,255,309,000 after buying an additional 472,067 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Celgene Corporation by 4.4% in the 1st quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock worth $816,733,000 after buying an additional 276,089 shares in the last quarter. Pioneer Investment Management Inc. boosted its position in shares of Celgene Corporation by 15.7% in the 1st quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock worth $650,911,000 after buying an additional 710,584 shares in the last quarter. Finally, Clearbridge Investments LLC boosted its position in shares of Celgene Corporation by 24.1% in the 1st quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock worth $572,617,000 after buying an additional 892,392 shares in the last quarter. Institutional investors and hedge funds own 79.36% of the company’s stock.

Shares of Celgene Corporation (NASDAQ CELG) opened at 139.27 on Tuesday. The firm has a 50-day moving average of $139.64 and a 200 day moving average of $129.73. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $147.17. The firm has a market cap of $108.96 billion, a P/E ratio of 43.13 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same period in the previous year, the company earned $1.44 EPS. The company’s revenue for the quarter was up 18.7% on a year-over-year basis. On average, equities research analysts anticipate that Celgene Corporation will post $7.32 EPS for the current fiscal year.

CELG has been the topic of a number of recent research reports. BidaskClub upgraded shares of Celgene Corporation from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 14th. Oppenheimer Holdings, Inc. set a $148.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a report on Wednesday, June 14th. Leerink Swann upgraded shares of Celgene Corporation from a “market perform” rating to an “outperform” rating and upped their target price for the company from $94.42 to $150.00 in a report on Friday, June 16th. They noted that the move was a valuation call. William Blair restated an “outperform” rating on shares of Celgene Corporation in a report on Monday, June 26th. Finally, BTIG Research lowered shares of Celgene Corporation from a “buy” rating to a “neutral” rating and upped their target price for the company from $96.93 to $131.70 in a report on Friday, June 30th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and twenty-two have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $150.60.

In related news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ernest Mario sold 18,506 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the sale, the director now owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 46,233 shares of company stock valued at $6,268,259. Corporate insiders own 0.95% of the company’s stock.

TRADEMARK VIOLATION WARNING: “7,800 Shares in Celgene Corporation (CELG) Acquired by Walter & Keenan Financial Consulting Co. MI ADV” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://ledgergazette.com/2017/10/10/7800-shares-in-celgene-corporation-celg-acquired-by-walter-keenan-financial-consulting-co-mi-adv.html.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply